Chapter 8: Drug-resistant tuberculosis

References

• Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 2000;4(9):796–806.
   PubMed Web of Science ®Google Scholar
• Dheda K, Gumbo T, Maartens G, Lancet Respiratory Medicine drug-resistant tuberculosis Commission group, et al. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med. 2019;7(9):820–826. doi:10.1016/S2213-2600(19)30263-2.
   PubMed Web of Science ®Google Scholar
• Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med. 2012;367(10):931–936. doi:10.1056/NEJMra1205429.
   PubMed Web of Science ®Google Scholar
• Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008;149(2):123–134. doi:10.7326/0003-4819-149-2-200807150-00008.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis , 27–29 October 2020. 2021. https://www.who.int/publications/i/item/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis. Accessed August 26, 2021.
   Google Scholar
• World Health Organization. Global Tuberculosis Report. 2020.
   Google Scholar
• LaFreniere M, Dam D, Strudwick L, McDermott S. Tuberculosis drug resistance in Canada: 2018. Can Commun Dis Rep. 2020;46(1):9–15. doi:10.14745/ccdr.v46i01a02.
   PubMedGoogle Scholar
• Gangadharam PR. Drug resistance in tuberculosis: it’s not always the patient’s fault!. Tuber Lung Dis. 1993;74(1):65–67. doi:10.1016/0962-8479(93)90074-8.
   PubMedGoogle Scholar
• Long R, Chui L, Kakulphimp J, Zielinski M, Talbot J, Kunimoto D. Postsanatorium pattern of antituberculous drug resistance in the Canadian-born population of western Canada: effect of outpatient care and immigration. Am J Epidemiol. 2001;153(9):903–911. doi:10.1093/aje/153.9.903.
   PubMed Web of Science ®Google Scholar
• Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis. 1965;92(5):687–703. doi:10.1164/arrd.1965.92.5.687.
   PubMedGoogle Scholar
• Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med. 1980;1(2):231–241. doi:10.1016/S0272-5231(21)00072-1.
   PubMed Web of Science ®Google Scholar
• Iseman M. Drug-resistant tuberculosis. In: Iseman M, ed. A Clinician’s Guide to Tuberculosis. Philadelphia, PA: Lippincott, Williams & Wilkins; 2000: 323–354.
   Google Scholar
• Stewart SM, Crofton JW. The Clinical Significance of Low Degrees of Drug Resistance in Pulmonary TUBERCULOSIS. Am Rev Respir Dis. 1964;89:811–829. doi:10.1164/arrd.1964.89.6.811.
   PubMedGoogle Scholar
• Iseman MD, Madsen LA. Drug-resistant tuberculosis. Clin Chest Med. 1989;10(3):341–353. doi:10.1016/S0272-5231(21)00637-7.
   PubMed Web of Science ®Google Scholar
• Toman K. Tuberculosis Case-Finding and Chemotherapy. Geneva, Switzerland: World Health Organization; 1979.
   Google Scholar
• Costello HD, Caras GJ, Snider DE.Jr. Drug resistance among previously treated tuberculosis patients, a brief report. Am Rev Respir Dis. 1980;121(2):313–316. doi:10.1164/arrd.1980.121.2.313.
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis. 1998;2(3):187–199.
   PubMed Web of Science ®Google Scholar
• Dheda K, Lenders L, Magombedze G, et al. Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis. Am J Respir Crit Care Med. 2018;198(9):1208–1219. doi:10.1164/rccm.201711-2333OC.
   PubMed Web of Science ®Google Scholar
• Shenje J, Ifeoma Adimora-Nweke F, Ross IL, et al. Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. EBioMedicine. 2015;2(11):1640–1649. doi:10.1016/j.ebiom.2015.09.025.
   PubMed Web of Science ®Google Scholar
• Pouplin T, Bang ND, Toi PV, et al. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. BMC Infect Dis. 2016;16:144 doi:10.1186/s12879-016-1470-x.
   PubMed Web of Science ®Google Scholar
• Long R, Barrie J, Stewart K, Peloquin CA. Treatment of a tuberculous empyema with simultaneous oral and intrapleural antituberculosis drugs. Can Respir J. 2008;15(5):241–243. doi:10.1155/2008/747206.
   PubMed Web of Science ®Google Scholar
• Braden CR, Morlock GP, Woodley CL, et al. Simultaneous infection with multiple strains of Mycobacterium tuberculosis. Clin Infect Dis. 2001;33(6):e42–e47. doi:10.1086/322635.
   PubMed Web of Science ®Google Scholar
• Rinder H, Mieskes KT, Loscher T. Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2001;5(4):339–345.
   PubMed Web of Science ®Google Scholar
• Streicher EM, Bergval I, Dheda K, et al. Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. Antimicrob Agents Chemother. 2012;56(5):2420–2427. doi:10.1128/AAC.05905-11.
   PubMed Web of Science ®Google Scholar
• Warren RM, Victor TC, Streicher EM, et al. Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med. 2004;169(5):610–614. doi:10.1164/rccm.200305-714OC.
   PubMed Web of Science ®Google Scholar
• Zetola NM, Modongo C, Moonan PK, et al. Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests. J Infect Dis. 2014;209(11):1754–1763. doi:10.1093/infdis/jiu040.
   Web of Science ®Google Scholar
• Small PM, McClenny NB, Singh SP, Schoolnik GK, Tompkins LS, Mickelsen PA. Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures. J Clin Microbiol. 1993;31(7):1677– 1682. doi:10.1128/jcm.31.7.1677-1682.mono-resistant1993.
   PubMed Web of Science ®Google Scholar
• Taylor AB, Kurbatova EV, Cegielski JP. Prevalence of anti-tuberculosis drug resistance in foreign-born tuberculosis cases in the U.S. and in their countries of origin. PLoS One. 2012;7(11):e49355. doi:10.1371/journal.pone.0049355.
   PubMed Web of Science ®Google Scholar
• Kunimoto D, Sutherland K, Wooldrage K, et al. Transmission characteristics of tuberculosis in the foreign-born and the Canadian-born populations of Alberta, Canada. Int J Tuberc Lung Dis. 2004;8(10):1213–1220.
   PubMed Web of Science ®Google Scholar
• Dean AS, Zignol M, Cabibbe AM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008 Jandoi:10.1371/journal.pmed.1003008.
   PubMed Web of Science ®Google Scholar
• Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science. 1953;118(3063):297–299. 1953-09-11doi:10.1126/science.118.3063.297.
   PubMed Web of Science ®Google Scholar
• Cohn ML, Kovitz C, Oda U, Middlebrook G. Studies on isoniazid and tubercle bacilli. II. The growth requirements, catalase activities, and pathogenic properties of isoniazid-resistant mutants. Am Rev Tuberc. 1954;70(4):641–664. Octdoi:10.1164/art.1954.70.4.641.
   PubMedGoogle Scholar
• Riley RL, Mills CC, O’grady F, Sultan LU, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis. 1962;85:511–525. doi:10.1164/arrd.1962.85.4.511.
   PubMed Web of Science ®Google Scholar
• Pym AS, Domenech P, Honore N, Song J, Deretic V, Cole ST. Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. Mol Microbiol. 2001;40(4):879–889. doi:10.1046/j.1365-2958.2001.02427.x.
   Web of Science ®Google Scholar
• Siminel M, Bungezianu G, Anastasatu C. The risk of infection and disease in contacts with patients excreting Mycobacterium tuberculosis sensitive and resistant to isoniazid. Bull Int Union Tuberc. 1979;54(3-4):263.
   Google Scholar
• Snider DE, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis. 1985;132(1):125–132. doi:10.1164/arrd.1985.132.1.125.
   PubMedGoogle Scholar
• van Soolingen D, Borgdorff MW, de Haas PE, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis. 1999;180(3):726–736. doi:10.1086/314930.
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia ML, Ponce de Leon A, Jimenez-Corona ME, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med. 2000;160(5):630–636. Mar 13 doi:10.1001/archinte.160.5.630.
   PubMedGoogle Scholar
• Godfrey-Faussett P, Sonnenberg P, Shearer SC, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet. 2000;356(9235):1066–1071. doi:10.1016/S0140-6736(00)02730-6.
   PubMed Web of Science ®Google Scholar
• Toit K, Altraja A, Acosta CD, et al. A four-year nationwide molecular epidemiological study in Estonia: risk factors for tuberculosis transmission. Public Health Action. 2014;4(Suppl 2):S34–S40. doi:10.5588/pha.14.0045.
   Google Scholar
• Burgos M, de Reimer K, Small P, Hopewell P, Daley C. Differential transmission of drug-resistant and drug susceptible Mycobacterium tuberculosis. Paper presented at: Abstracts of the 36th Tuberculosis and Leprosy Research Conference (Abstract). 2001. 206–11.
   Google Scholar
• Munsiff SS, Nivin B, Sacajiu G, Mathema B, Bifani P, Kreiswirth BN. Persistence of a highly resistant strain of tuberculosis in New York City during 1990-1999. J Infect Dis. 2003;188(3):356–363. doi:10.1086/376837.
   PubMed Web of Science ®Google Scholar
• Borrell S, Teo Y, Giardina F, et al. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol Med Public Health. 2013;2013(1):65–74. doi:10.1093/emph/eot003.
   PubMedGoogle Scholar
• de Vos M, Muller B, Borrell S, et al. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother. 2013;57(2):827–832. doi:10.1128/AAC.01541-12.
   PubMed Web of Science ®Google Scholar
• Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis. 2003;3(1):13–21. doi:10.1016/S1473-3099(03)00483-3.
   PubMed Web of Science ®Google Scholar
• Schaaf HS, Marais BJ, Hesseling AC, Gie RP, Beyers N, Donald PR. Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatr. 2006-05 2006;95(5):523–528. doi:10.1080/08035250600675741.
   PubMed Web of Science ®Google Scholar
• Moss AR, Alland D, Telzak E, et al. A city-wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease. 1997;1(2):115–121.
   PubMed Web of Science ®Google Scholar
• Drobniewski F, Balabanova Y, Nikolayevsky V, et al. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA. 2005;293(22):2726–2731. doi:10.1001/jama.293.22.2726.
   PubMed Web of Science ®Google Scholar
• Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (London, England). 2006;368(9547):1575–1580. 2006-11-04 doi:10.1016/S0140-6736(06)69573-1.
   PubMed Web of Science ®Google Scholar
• Sultana ZZ, Hoque FU, Beyene J, et al. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):51 doi:10.1186/s12879-020-05749-2.
   PubMed Web of Science ®Google Scholar
• Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One. 2009;4(5):e5561 doi:10.1371/journal.pone.0005561.
   PubMed Web of Science ®Google Scholar
• Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007;196Suppl 1 (Suppl 1):S86–S107. doi:10.1086/518665.
   Google Scholar
• Hirama T, Sabur N, Derkach P, et al. Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010-2016. Can Commun Dis Rep. 2020;46(4):84–92. doi:10.14745/ccdr.v46i04a05.
   PubMedGoogle Scholar
• Long R, Langlois-Klassen D. Increase in multidrug-resistant tuberculosis (MDR-TB) in Alberta among foreign-born persons: implications for tuberculosis management. Can J Public Health. 2013;104(1):e22-7–e27.
   Web of Science ®Google Scholar
• Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. doi:10.1093/cid/ciw376.
   PubMed Web of Science ®Google Scholar
• Curry National Tuberculosis Center and California Department of Health Services. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 3rd ed. San Francisco, CA; 2016.
   Google Scholar
• Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017;64(2):111–115. doi:10.1093/cid/ciw778.
   PubMedGoogle Scholar
• Shin SS, Asencios L, Yagui M, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int j Tuberc Lung Dis. 2012;16(11):1538–1543. doi:10.5588/ijtld.12.0071.
   PubMed Web of Science ®Google Scholar
• Jacobson KR, Theron D, Kendall EA, et al. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis. 2013;56(4):503–508. doi:10.1093/cid/cis920.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahuja SD, Akkerman OW, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821–834. doi:10.1016/S0140-6736(18)31644-1.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis. 2018. Geneva, Switzerland. 9789241514842. https://apps.who.int/iris/handle/10665/275469
   Google Scholar
• Crofton SJ, Chaulet P, Maher D, et al. Guidelines for the Management of Drug-Resistant Tuberculosis. by Sir John Crofton, Pierre Chaulet and Dermot Maher; with contributions from Jacques Grosset …, et al. Geneva: World Health Organization; 1997.
   Google Scholar
• Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist. 2006;12(1):7–11. doi:10.1089/mdr.2006.12.7.
   PubMed Web of Science ®Google Scholar
• Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM, Chan RC. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2004;48(2):596–601. doi:10.1128/AAC.48.2.596-601.2004.
   Web of Science ®Google Scholar
• Almeida D, Ioerger T, Tyagi S, et al. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60(8):4590–4599. doi:10.1128/AAC.00753-16.
   PubMed Web of Science ®Google Scholar
• Nguyen TVA, Anthony RM, Banuls AL, Nguyen TVA, Vu DH, Alffenaar JC. Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. Clin Infect Dis. 2018;66(10):1625–1630. doi:10.1093/cid/cix992.
   PubMed Web of Science ®Google Scholar
• Fregonese F, Ahuja SD, Akkerman OW, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018;6(4):265–275. doi:10.1016/S2213-2600(18)30078-X.
   PubMed Web of Science ®Google Scholar
• Piatek AS, Telenti A, Murray MR, et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother. 2000;44(1):103– 110. doi:10.1128/AAC.44.1.103-110.2000.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992;358(6387):591–593. doi:10.1038/358591a0.
   PubMed Web of Science ®Google Scholar
• Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621–629. doi:10.1016/S1473-3099(10)70139-0.
   PubMed Web of Science ®Google Scholar
• Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS One. 2011;6(7):e22927. doi:10.1371/journal.pone.0022927.
   PubMed Web of Science ®Google Scholar
• Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(2):223–234. doi:10.1016/S1473-3099(16)30407-8.
   PubMed Web of Science ®Google Scholar
• WHO Guidelines Approved by the Guidelines Review Committee. WHO Treatment Guidelines for Isoniazid-Resistant Tuberculosis: Supplement to the WHO Treatment Guidelines for Drug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organization; 2018.
   Google Scholar
• Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647–650. doi:10.1016/0140-6736(93)90417-f.
   PubMed Web of Science ®Google Scholar
• Bishai WR, Graham NM, Harrington S, et al. Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med. 1996;334(24):1573–1576. doi:10.1056/NEJM199606133342404.
   PubMed Web of Science ®Google Scholar
• Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis. 2004;38(5):731–736. doi:10.1086/381675.
   PubMed Web of Science ®Google Scholar
• Burman W, Benator D, Vernon A, Consortium TT. Use of antiretroviral therapy during treatment of active tuberculosis with a rifabutin-based regimen. Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections. 2003.
   Google Scholar
• el-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis. 1998;26(5):1148–1158. doi:10.1086/520275.
   PubMed Web of Science ®Google Scholar
• Li J, Munsiff SS, Driver CR, Sackoff J. Outcome of HIV-infected tuberculosis patients treated with rifabutin or rifampin-based regimens, New York City, 1997-2000 (late-breaker abstract). Paper presented at: Program and Abstracts of the International Union against TB and Lung Disease (IUATLD) World Conference on Lung Health. Paris(Abstract). 2003.
   Google Scholar
• Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353(9167):1843–1847. doi:10.1016/s0140-6736(98)11467-8.
   PubMed Web of Science ®Google Scholar
• Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358(9294):1687–1693. doi:10.1016/S0140-6736(01)06712-5.
   PubMed Web of Science ®Google Scholar
• Hong Kong Chest Service Tuberculosis Research Centre. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis. 1977;115(5):727–735. doi:10.1164/arrd.1977.115.5.727.
   PubMedGoogle Scholar
• McDonald FW. Study of triple versus double drug therapy of cavitary tuberculosis. Study 29. Preliminary report. Paper presented at: 27th Pulmonary Disease Research Conference, VA Armed Forces, Washington, DC(Abstract). 1968.
   Google Scholar
• Nguyen D, Brassard P, Westley J, et al. Widespread pyrazinamide-resistant Mycobacterium tuberculosis family in a low-incidence setting. J Clin Microbiol. 2003;41(7):2878 doi:10.1128/JCM.41.7.2878:–2883.
   PubMed Web of Science ®Google Scholar
• Yee DP, Menzies D, Brassard P. Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec. Int J Tuberc Lung Dis. 2012;16(5):604–609. doi:10.5588/ijtld.11.0376.
   PubMed Web of Science ®Google Scholar
• Blumberg HM, Burman WJ, Chaisson RE, American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603–662. doi:10.1164/rccm.167.4.603.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the Programmatic Management of Drug- Resistant Tuberculosis. 2005. Geneva, Switzerland: World Health Organization. WHO/htm/tb/2006.361.
   Google Scholar
• Minion J, Gallant V, Wolfe J, Jamieson F, Long R. Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. PLoS One. 2013;8(1):e53466. doi:10.1371/journal.pone.0053466.
   PubMed Web of Science ®Google Scholar
• Hersi A, Elwood K, Cowie R, Kunimoto D, Long R. Multidrug-resistant tuberculosis in Alberta and British Columbia, 1989 to 1998. Can Respir J. 1999;6(2):155–160. Mar-Apr doi:10.1155/1999/456395.
   PubMedGoogle Scholar
• Long R, Nobert E, Chomyc S, et al. Transcontinental spread of multidrug-resistant Mycobacterium bovis. Am J Respir Crit Care Med. 1999;159(6):2014–2017. doi:10.1164/ajrccm.159.6.9809076.
   PubMed Web of Science ®Google Scholar
• Avendano M, Goldstein RS. Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients. Can Respir J. 2000;7(5):383–389. doi:10.1155/2000/457905.
   PubMedGoogle Scholar
• Brode SK, Varadi R, McNamee J, et al. Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients. Can Respir J. 2015;22(2):97–102. doi:10.1155/2015/359301.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Operational Handbook on Tuberculosis. 2020. chap Module 4: treatment - drug-resistant tuberculosis treatment. Geneva, Switzerland.
   Google Scholar
• Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(10):e93–e142. doi:10.1164/rccm.201909-1874ST.
   PubMed Web of Science ®Google Scholar
• Ahmad Khan F, Salim MAH, Du Cros P, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J. 2017;50(1):1700061. doi:10.1183/13993003.00061-2017.
   PubMed Web of Science ®Google Scholar
• Abidi S, Achar J, Assao Neino MM, et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 2020;55(3):1901467. doi:10.1183/13993003.01467-2019.
   PubMed Web of Science ®Google Scholar
• Guglielmetti L, Le Du D, Jachym M, for the MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 2015;60(2):188–194. doi:10.1093/cid/ciu786.
   PubMed Web of Science ®Google Scholar
• Mase SR, Ramsay A, Ng V, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2007;11(5):485–495.
   PubMed Web of Science ®Google Scholar
• Management of Drug-Resistant Tuberculosis in Children: A Field Guide. Boston, USA: The Sentinel Project for Pediatric Drug-Resistant Tuberculosis; November 2018, Fourth edition.
   Google Scholar
• World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva, Switzerland: World Health Organization; 2019.
   Google Scholar
• Garcia-Prats AJ, Svensson EM, Weld ED, Schaaf HS, Hesseling AC. Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children. Int J Tuberc Lung Dis. 2018;22(5):15–23. doi:10.5588/ijtld.17.0355.
   PubMedGoogle Scholar
• American Academy of Pediatrics. chap Tuberculosis. In: American Academy of Pediatrics , ed. Red Book: 2021–2024 Report of the Committee on Infectious Diseases. 32nd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2021;786–814.
   Google Scholar
• van Altena R, Dijkstra JA, van der Meer ME, et al. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2017;61(3):e01400-16. doi:10.1128/AAC.01400-16.
   Web of Science ®Google Scholar
• Sabur NF, Brar MS, Wu L, Brode SK. Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB). BMC Infect Dis. 2021;21(1):254. Mar 10 doi:10.1186/s12879-021-05947-6.
   PubMed Web of Science ®Google Scholar
• Bisson GP, Bastos M, Campbell JR, et al. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet. 2020;396(10248):402–411. doi:10.1016/S0140-6736(20)31316-7.
   PubMed Web of Science ®Google Scholar
• Daftary A, Mondal S, Zelnick J, et al. Dynamic needs and challenges of people with drug-resistant tuberculosis and HIV in South Africa: a qualitative study. Lancet Glob Health. 2021;9(4):e479–e488. doi:10.1016/S2214-109X(20)30548-9.
   PubMed Web of Science ®Google Scholar
• Loveday M, Hughes J, Sunkari B, et al. Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa. Clin Infect Dis. 2021;72(7):1158–1168. doi:10.1093/cid/ciaa189.
   PubMed Web of Science ®Google Scholar
• Akkerman OW, Odish OF, Bolhuis MS, et al. Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis. Clin Infect Dis. 2016;62(4):523–524. doi:10.1093/cid/civ921.
   PubMed Web of Science ®Google Scholar
• Tucker EW, Pieterse L, Zimmerman MD, et al. Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans. Antimicrob Agents Chemother. 2019;63(10):e00913-19. doi:10.1128/AAC.00913-19.
   PubMed Web of Science ®Google Scholar
• Holdiness MR. Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet. 1985;10(6):532–534. doi:10.2165/00003088-198510060-00006.
   PubMed Web of Science ®Google Scholar
• WHO Guidelines Approved by the Guidelines Review Committee. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organization; 2014.
   Google Scholar
• Haley CA, Macias P, Jasuja S, et al. Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States. Emerg Infect Dis. 2021;27(1):332–334. doi:10.3201/eid2701.203766.
   Web of Science ®Google Scholar
• Medical Economics Staff, PDR Staff. Physicians’ Desk Reference 2003. 57th ed. North Olmsted, OH: Medical Economics Co.; 2003.
   Google Scholar
• Yew WW, Wong CF, Wong PC, Lee J, Chau CH. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin. Clin Infect Dis. 1993;17(2):288–289. doi:10.1093/clinids/17.2.mono-resistant288.
   Web of Science ®Google Scholar
• Lan Z, Ahmad N, Baghaei P, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8(4):383–394. doi:10.1016/S2213-2600(20)30047-3.
   PubMed Web of Science ®Google Scholar
• Fox GJ, Mitnick CD, Benedetti A, Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, et al. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis. 2016;62(7):887–895. doi:10.1093/cid/ciw002.
   PubMed Web of Science ®Google Scholar
• Ortiz-Brizuela E. Effectiveness and Safety of Lung Resection Surgery among Patients with Pulmonary Multi-Drug Resistant Tuberculosis [Masters Thesis]. McGill University; 2021.
   Google Scholar
• Conradie F, Diacon AH, Ngubane N, Nix-TB Trial Team, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893–902. doi:10.1056/NEJMoa1901814.
   PubMed Web of Science ®Google Scholar
• Global Alliance for TB Drug Development. A Phase 3 Partially-blinded , Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB), Pre-XDR-TB or Treatment Intolerant or Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB). Clinical trial registration. 2021. NCT03086486. February 26, 2021. Accessed 2021-12-27.
   Google Scholar
• Working Group on New TB Drugs. Clinical Pipeline. https://www.newtbdrugs.org/pipeline/clinical.
   Google Scholar
• Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA. 1993;270(1):65–8.
   Web of Science ®Google Scholar